Advertisement

Prostate Cancer Chemotherapy

Closing Out a Century and Opening a New One
  • Jeffrey M. Kamradt
  • Kenneth J. Pienta
Chapter
Part of the Contemporary Cancer Research book series (CCR)

Abstract

The systemic treatment of metastatic prostate cancer began with the discovery by Huggins and Hodges of the effects of estrogen in patients with advanced disease (36–38). However, it became clear that the majority of patients become refractory to this treatment. Many trials have investigated a multitude of agents, searching for an effective treatment for men with hormone refractory disease. These studies were limited by the natural history of the disease and the limitation of radiological studies to assess response, and progress was slow. The emergence of prostate specific antigen (PSA) as both a surrogate marker of disease burden and response in patients with advanced prostate cancer revolutionized the study of chemotherapy in hormone refractory prostate cancer. Response was now easily quantifiable. Also at this time, chemotherapy regimens began to be designed based upon evidence of preclinical activity. New agents also became available with increased activity. Currently, a variety of chemotherapy regimens are available which can substantially reduce tumor burden in approx 50% of patients treated. This reduction in disease has been associated with improved quality of life. New regimens with enhanced activity are being developed. Also, research to investigate the expanded role of chemotherapy prior to prostatectomy or radiation therapy is currently underway.

Keywords

Prostate Cancer Prostate Specific Antigen National Comprehensive Cancer Network National Comprehensive Cancer Network Advanced Prostate Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ansfield, F. J., J. Schroeder, and A. R. Curreri. 1962. Five years clinical experience with 5-fluorouracil. DAMA 181: 295–299.Google Scholar
  2. 2.
    Atkins, J. N., H. B. Muss, D. Case, et al. 1991. High-dose 24-hour infusion of 5-fluorouracil in metastatic prostate cancer. A phase II trial of the Piedmont Oncology Association. Am. J. Clin. Oncol. 14: 526–529.PubMedCrossRefGoogle Scholar
  3. 3.
    Attivissimo, L. A., J. V. Fetten, and W. Kreis. 1996. Symptomatic improvement associated with combined estramustine and vinblastine chemotherapy for metastatic prostate cancer. Am. J. Clin. Oncol. 19: 581–583.PubMedCrossRefGoogle Scholar
  4. 4.
    Babaian, R. J. and S. D. Hsu. 1984. Chemotherapy of hormone refractory carcinoma of prostate with 5-fluorouracil, adriamycin, and mitomycin C. Urology 23: 272–275.PubMedCrossRefGoogle Scholar
  5. 5.
    Batra, S., R. Karlsson, and L. Witt. 1996. Potentiation by estramustine of the cytotoxic effect of vinblastine and doxorubicin in prostatic tumor cells. Int. J. Cancer 68: 644–649.PubMedCrossRefGoogle Scholar
  6. 6.
    Beckley, S., L. Z. Wajsman, N. H. Slack, and G. P. Murphy. 1981. Chemotherapy in metastatic, hormone refractory prostatic cancer using chlorambucil in combination with prednisolone versus conjugate, prednimustine (Leo 1031). Urology 17: 446–448.PubMedCrossRefGoogle Scholar
  7. 7.
    Ben-Josef, E., S. Han, W. Mertens, et al. 1999. Neoadjuvant estramustine/etoposide followed by concurrent estramustine and definitive radiotherapy for locally advanced prostate cancer. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 18: Al238.Google Scholar
  8. 8.
    Berry, J. and R. N. MacDonald. 1982. Cisplatin, cyclophosphamide and prednisone therapy for stage D prostatic cancer. Cancer Treat. Rep. 66: 1403–1404.PubMedGoogle Scholar
  9. 9.
    Bishop, M. C., C. Selby, and M. Taylor. 1985. Plasma hormone levels in patients with prostatic carcinoma treated with diethylstilbestrol and estramustine. Br. J. Urol. 57: 542–547.PubMedCrossRefGoogle Scholar
  10. 10.
    Blumenstein, B., E. D. Crawford, J. H. Saiers, R. L. Stephens, S. E. Rivkin, and C. A. Coltman Jr. 1993. Doxorubicin, mitomycin C and 5-fluorouracil in the treatment of hormone refractory adenocarcinoma of the prostate: a Southwest Oncology Group study. J. Urol. 150: 411–413.PubMedGoogle Scholar
  11. 11.
    Bolla, M., D. Gonzalez, P. Warde, et al. 1997. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N. Engl. J. Med. 337: 295–300.PubMedCrossRefGoogle Scholar
  12. 12.
    Brausi, M., W. G. Jones, S. D. Fossa, et al. 1995. High dose epirubicin is effective in measurable metastatic prostate cancer: a phase II study of the EORTC Genitourinary Group (see comments). Eur. J. Cancer 31A: 1622–1626.CrossRefGoogle Scholar
  13. 13.
    Bui, N. B., J. Chauvergne, R. Brunet, P. Richaud, C. Lagarde, and M. Le Guillou. 1986. Metastatic cancer of the prostate: phase II study of spirogeranium (NSC 192965). Bull. Cancer (Paris) 73: 65–67.Google Scholar
  14. 14.
    Canobbio, L., D. Guarneri, L. Miglietta, A. Decensi, F. Oneto, and F. Boccardo. 1993. Carboplatin in advanced hormone refractory prostatic cancer patients. Eur. J. Cancer 29M 2094–2096.CrossRefGoogle Scholar
  15. 15.
    Catane, R., J. H. Kaufman, S. Madajewicz, A. Mittelman, and G. P. Murphy. 1978. Prednimustine therapy for advanced prostatic cancer. Br. J. Urol. 50: 29–32.PubMedCrossRefGoogle Scholar
  16. 16.
    Dahllof, B., A. Billstrom, F. Cabal, and B. Hartley-Asp. 1993. Estramustine depolymerizes microtubules by binding to tubulin. Cancer Res. 53: 4573–4581.PubMedGoogle Scholar
  17. 17.
    Dawson, N. A., S. Halabi, V. Hars, E. J. Small, and N. J. Vogelzang. 1999. Prostate specific antigen decline as a predictor of survival: Cancer and Leukemia Group B 9181. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 18: Al209.Google Scholar
  18. 18.
    deKernion, J.B. and A. Lindner. 1984. Chemotherapy of hormonally unresponsive prostatic carcinoma. Urol. Clin. N. Am. 11: 319–326.Google Scholar
  19. 19.
    Dexeus, F., C. J. Logothetis, M. L. Samuels, E. Hossan, and A. C. Von Eschenbach. 1985. Continuous infusion of vinblastine for advanced hormone refractory prostate cancer. Cancer Treat. Rep. 69: 885–886.PubMedGoogle Scholar
  20. 20.
    Dexeus, F. H., C. Logothetis, M. L. Samuels, et al. 1986. Phase II study of spirogeranium in metastatic prostate cancer. Cancer Treat. Rep. 70: 1129–1130.PubMedGoogle Scholar
  21. 21.
    Diaz, J. F. and J. M. Andreu. 1993. Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry and competition. Biochemistry 32: 2747–2755.PubMedCrossRefGoogle Scholar
  22. 22.
    Dimopoulos, M. A., C. Panopoulos, C. Bamia, et al. 1997. Oral estramustine and oral etoposide for hormone refractory prostate cancer. Urology 50: 754–758.PubMedCrossRefGoogle Scholar
  23. 23.
    Drelichman, A., R. Brownlee, and M. Al-Sarraf. 1981. Phase II study of hexamethylmelamine for disseminated prostatic carcinoma. Cancer Clin. Trials 4: 309–312.PubMedGoogle Scholar
  24. 24.
    Drelichman, A., D. A. Decker, M. Al-Saraff, and C. B. Dhabuwala. 1982. M-AMSA in disseminated prostatic carcinoma: a phase II study. Cancer Treat. Rep. 66: 1993–1994.PubMedGoogle Scholar
  25. 25.
    Drelichman, A., J. Oldford, and M. Al-Sarraf. 1985. Evaluation of cyclophosphamide, adriamycin and cis-platinum (CAP) in patients with disseminated prostatic carcinoma. A phase II study. Am. J. Clin. Oncol. 8: 255–259.PubMedCrossRefGoogle Scholar
  26. 26.
    Eisenberger, M. A. 1988. Chemotherapy for prostate cancer. NCI Monographs 7: 151–163.PubMedGoogle Scholar
  27. 27.
    Eisenberger, M., M. Meyer, P. Lenehan, et al. 1999. Suramin induced decrease in PSA is associated with prolonged objective progression-free and overall survival in hormone refractory prostate cancer. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 18: Al208.Google Scholar
  28. 28.
    Eisenberger, M. A., R. Simon, and P. J. O’Dwyer. 1985. A re-evaluation of non-hormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J. Clin. Oncol. 3: 827–841.PubMedGoogle Scholar
  29. 29.
    Eklov, S., J. E. Westlin, G. Rikner, and S. Nilsson. 1994. Estramustine potentiates the radiation effect in human prostate tumor transplant in nude mice. Prostate 24: 39–45.PubMedCrossRefGoogle Scholar
  30. 30.
    Ellerhorst, J. A., S. Tu, R. J. Amato, et al. 1997. Phase II trail of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer. Clin. Cancer Res. 3: 2371–2376.PubMedGoogle Scholar
  31. 31.
    Fuse, H., Y. Muraishi, Y. Fujishiro, and T. Katayama. 1996. Etoposide, epirubicin and carboplatin in hormone refractory prostate cancer. Int. Urol. Nephrol. 28: 79–85.PubMedCrossRefGoogle Scholar
  32. 32.
    Gunnarsson, P. 0., T. Davidsson, S. B. Andersson, C. Backman, and S. A. Johansson. 1990. Impairment of estramustine phosphate absorption by concurrent intake of milk and food. Eur. J. Clin. Pharmacol. 38: 189–193.Google Scholar
  33. 33.
    Hansen, R., T. Moynihan, P. Beatty, et al 1991. Continuous systemic 5-fluorouracil infusion in refractory prostatic cancer. Urology 37: 358–361.PubMedCrossRefGoogle Scholar
  34. 34.
    Hudes, G. R., R. Greenberg, R. L. Krigel, et al. 1992. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone refractory prostate cancer. J. Clin. Oncol. 10: 1754–1761.PubMedGoogle Scholar
  35. 35.
    Hudes, G. R., F. Nathan, C. Khater, et al. 1997. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone refractory prostate cancer. J. Clin. Oncol. 15: 3156–3163.PubMedGoogle Scholar
  36. 36.
    Huggins, C. and C. Hodges. 1941. Studies on prostatic cancer. I: The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1: 293–297.Google Scholar
  37. 37.
    Huggins, C., W. W. Scott, and C. V. Hodges. 1941. Studies on prostatic cancer III. The effects of fever, of deoxycorticosterone and of estrogen on clinical patients with metastatic carcinoma of the prostate. J. Urol. 46: 997–1001.Google Scholar
  38. 38.
    Huggins, C., R. E. Stevens, and C. Hodges. 1941. Studies on prostatic cancer. II: The effects of castration on advanced carcinoma of the prostate gland. Arch. Surg. 43: 209–223.CrossRefGoogle Scholar
  39. 39.
    Hussain, M. H., K. J. Pienta, B. G. Redman, G. D. Cummings, and L. E. Flaherty. 1994. Oral etoposide in the treatment of hormone refractory prostate cancer. Cancer 74: 100–103.PubMedCrossRefGoogle Scholar
  40. 40.
    Ihde, D. C., P. A. Bunn, M. H. Cohen, et al. 1980. Effective treatment of hormonally-unresponsive metastatic carcinoma of the prostate with adriamycin and cyclophosphamide. Methods of documenting tumor response and progression. Cancer 45: 1300–1310.PubMedCrossRefGoogle Scholar
  41. 41.
    Izbicki, R. M., M. H. Amer, and M. Al-Sarraf. 1979. Combination of adriamycin and cyclophosphamide in the treatment of metastatic prostatic carcinoma. Cancer Treat. Rep. 63: 999–1001.PubMedGoogle Scholar
  42. 42.
    Jones, W. G., S. D. Fossa, L. Denis, et al. 1983. An EORTC phase II study of vindesine in advanced prostate cancer. Eur. J. Cancer Clin. Oncol. 19: 583–588.PubMedCrossRefGoogle Scholar
  43. 43.
    Kamradt, J. M., M. A. Walsh, S. K. Brumfield, J. F. Williams, and K. J. Pienta. 1999. Docetaxel and estramustine: activity in preclinical models of prostate cancer. Proc. Annu. Meet. Am. Assoc. Cancer Res. 40: A1553.Google Scholar
  44. 44.
    Kantoff, P. W., C. Block, L. Letvak, and M. George. 1993. 14-day continuous infusion of mitoxantrone in hormone refractory metastatic adenocarcinoma of the prostate. Am. J. Clin. Oncol. 16: 489–491.Google Scholar
  45. 45.
    Karr, J. P., Z. Wajsman, R. Y. Kirdani, G. P. Murphy, and A. A. Sandberg. 1980. Effects of diethylstilbestrol and estramustine phosphate on serum sex hormone binding globulin and testosterone levels in prostate cancer patients. J. Urol. 124: 232–236.PubMedGoogle Scholar
  46. 46.
    Kasimis, B. S., E. M. Moran, J. B. Miller, et al. 1983. Treatment of hormone-resistant metastatic carcinoma of the prostate with 5-FU, doxorubicin and mitomycin (FAM): a preliminary report. Cancer Treat. Rep. 67: 937–939.PubMedGoogle Scholar
  47. 47.
    Kelly, W. K., H. I. Scher, M. Mazumdar, V. Vlamis, M. Schwartz, and S. D. Fossa. 1993. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J. Clin. Oncol. 11: 607–615.PubMedGoogle Scholar
  48. 48.
    Khil, M. S., J. H. Kim, L. J. Bricker, and J. C. Cerny. 1997. Tumor control of locally advanced prostate cancer following combined estramustine, vinblastine and radiation therapy. Cancer J. Sci. Am. 3: 289–296.PubMedGoogle Scholar
  49. 49.
    Kuss, R., S. Khoury, F. Richard, et al. 1980. Estramustine phosphate in the treatment of advanced prostatic cancer. Br. J. Urol. 52: 29–33.PubMedCrossRefGoogle Scholar
  50. 50.
    Kuzel, T. M., M. S. Tallman, D. Shevrin, et al. 1993. A phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer. An Illinois Cancer Center Study. Cancer 72: 1965–1968.PubMedCrossRefGoogle Scholar
  51. 51.
    Lerner, H. J. and T. R. Malloy. 1977. Hydroxyurea in stage D carcinoma of prostate. Urology 10: 35–38.PubMedCrossRefGoogle Scholar
  52. 52.
    Lloyd, R. E., S. E. Jones, S. E. Salmon, et al. 1976. Combination chemotherapy with adriamycin (NSC-123127) and cyclophosphamide (NSC-26271) for solid tumors: a phase II trial. Cancer Treat. Rep. 60: 77–83.PubMedGoogle Scholar
  53. 53.
    Loening, S. A., S. Beckley, M. F. Brady, et al. 1983. Comparison of estramustine phosphate, methotrexate and cis-platinum in patients with advanced, hormone refractory prostate cancer. J. Urol. 129: 1001–1006.PubMedGoogle Scholar
  54. 54.
    Loening, S. A., W. W. Scott, J. deKernion, et al. 1981. A comparison of hydroxyurea, methyl-chloroethyl-cyclohexy-nitrosourea and cyclophosphamide in patients with advanced carcinoma of the prostate. J. Urol. 125: 812–816.PubMedGoogle Scholar
  55. 55.
    Logothetis, C. J., M. L. Samuels, A. C. Von Eschenbach, et al. 1983. Doxorubicin, mitomycin-C and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer. J. Clin. Oncol. 1: 368–379.PubMedGoogle Scholar
  56. 56.
    Madsen, E. L., L. Bastholt, K. Bertelsen, C. Rose, and E. S. Nielsen. 1992. Weekly oral idarubicin in advanced prostatic cancer. A phase II study. Acta Oncol. 31: 337–340.PubMedCrossRefGoogle Scholar
  57. 57.
    Mahjoubi, M., M. Azab, M. Ghosn, C. Theodore, and J. P. Droz. 1990. Phase II trial of ifosfamide in the treatment of metastatic hormone refractory patients with prostatic cancer. Cancer. Invest. 8: 477–481.PubMedCrossRefGoogle Scholar
  58. 58.
    Merrin, C.E. 1979. Treatment of genitourinary tumors with cis-diammineplatinum (II): Experience in 250 patients. Cancer Treat. Rep. 63: 1579–1589.PubMedGoogle Scholar
  59. 59.
    Meyrin, C. E. and S. Beckley. 1979. The treatment of estrogen-resistant stage D carcinoma of the prostate with cis-diamminedichloroplatinum. Urology 13: 267–272.CrossRefGoogle Scholar
  60. 60.
    Merrin, C., W. Etra, Z. Wajsman, et al. 1976. Chemotherapy of advanced carcinoma of the prostate with 5-fluorouracil, cyclophosphamide and adriamycin. J. Urol. 115: 86–88.PubMedGoogle Scholar
  61. 61.
    Mittleman, A., S. K. Shukla, and G. P. Murphy. 1976. Extended therapy of stage D carcinoma of the prostate with oral estramustine phosphate. J. Urol. 115: 409–412.Google Scholar
  62. 62.
    Moore, G. E., I. D. J. Bross, and R. Ausman. 1968. Effects of 5-fluorouracil (NSC-19893) in 389 patients with cancer. Eastern Clinical Drug Evaluation Program. Cancer Chemother. Rep. 52: 641–653.PubMedGoogle Scholar
  63. 63.
    Moore, M. J., D. Osoba, K. Murphy, et al. 1994. Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. J. Clin. Oncol. 12: 689–694.PubMedGoogle Scholar
  64. 64.
    Moore, M. R., S. D. Graham, R. Birch, and L. Irwin. 1987. Phase II evaluation of mitoguazone in metastatic hormone-resistant prostate cancer: a Southeastern Cancer Study Group trial. Cancer Treat. Rep. 71: 89–90.PubMedGoogle Scholar
  65. 65.
    Moore, M. R., M. B. Troner, and P. DeSimone. 1986. Phase II evaluation of weekly cisplatin in metastatic hormone-resistant prostate cancer. A Southeastern Cancer Study Group trial. Cancer Treat. Rep. 70: 541–542.PubMedGoogle Scholar
  66. 66.
    Murphy, G. P., R. P. Gibbons, D. E. Johnson, et al. 1977. A comparison of estramustine phosphate and streptozotocin in patients with advanced prostatic carcinoma who have had extensive radiation. J. Urol. 118: 288–291.PubMedGoogle Scholar
  67. 67.
    Murphy, G. P., R. P. Gibbons, D. E. Johnson, et al. 1979. The use of estramustine and prednimustine versus prednimustine alone in advanced metastatic prostatic cancer patients who have received prior irradiation. J. Urol. 121: 763–765.PubMedGoogle Scholar
  68. 68.
    Murphy, G. P., R. L. Priore, and P. T. Scardino. 1988. Hormone refractory metastatic prostatic cancer treated with methotrexate, cyclophosphamide plus adriamycin, cis-platinum plus 5-fluorouracil plus cyclophosphamide. National Prostatic Cancer Project randomized trial. Urology 32: 33–40.PubMedCrossRefGoogle Scholar
  69. 69.
    Murphy, G. P. and N. H. Slack. 1980. Response criteria for the prostate of the USA National Prostatic Cancer Project. Prostate 1: 375–382.PubMedCrossRefGoogle Scholar
  70. 70.
    Muss, H. B., V. Howard, F. Richards, et al. 1981. Cyclophosphamide versus cyclophosphamide, methotrexate and 5-fluorouracil in advanced prostatic cancer: a randomized trial. Cancer 47: 1949–1953.PubMedCrossRefGoogle Scholar
  71. 71.
    Natale, R. B., A. Yagoda, and R. C. Watson. 1982. Phase II trial of AMSA in prostatic cancer. Cancer Treat. Rep. 66: 208–209.PubMedGoogle Scholar
  72. 72.
    O’Bryan, R. M., L. H. Baker, and J. F. Gottlieb. 1977. Dose response evaluation of Adriamycin in human neoplasia. Cancer 39: 1940.PubMedCrossRefGoogle Scholar
  73. 73.
    O’Bryan, R. M., J. K. Luce, and R. W. Talley. 1973. Phase II evaluation of Adriamycin in human neoplasia. Cancer 32: 1–8.PubMedCrossRefGoogle Scholar
  74. 74.
    Oesterling, J. E., D. W. Chan, and J. Epstein. 1988. Prostate specific antigen in preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J. Urol. 139: 766–772.PubMedGoogle Scholar
  75. 75.
    Osborne, C. K., B. A. Blumenstein, E. D. Crawford, G. R. Weiss, R. M. Bukowski, and N. R. Larrimer. 1992. Phase II study of platinum and mitoxantrone in metastatic prostate cancer: a Southwest Oncology Group Study. Eur. J. Cancer 28: 477–478.PubMedCrossRefGoogle Scholar
  76. 76.
    Osborne, C. K., A. Drelichman, D. D. Von Hoff, and E. D. Crawford. 1983. Mitoxantrone: modest activity in a phase II trial in advanced prostate cancer. Cancer Treat. Rep. 67: 1133–1135.PubMedGoogle Scholar
  77. 77.
    Petrylak, D. P., R. B. MacArthur, J. O’Connor, et al. 1999. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J. Clin. Oncol. 17: 958–967.PubMedGoogle Scholar
  78. 78.
    Pienta, K. J. and J. E. Lehr. 1993. Inhibition of prostate cancer growth by estramustine and etoposide: evidence for interaction at the nuclear matrix. J. Urol. 149: 1622–1625.PubMedGoogle Scholar
  79. 79.
    Pienta, K. J., H. Naik, and J. E. Lehr. 1996. Effect of estramustine, etoposide and taxol on prostate cancer cell growth in vitro and in vivo. Urology 48: 164–170.PubMedCrossRefGoogle Scholar
  80. 80.
    Pienta, K. J., B. G. Redman, R. Bandekar, et al. 1997. A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer. Urology 50: 401–407.PubMedCrossRefGoogle Scholar
  81. 81.
    Pienta, K. J., B. Redman, M. Hussain, et al. 1994. Phase II evaluation of oral estramustine and oral etoposide in hormone refractory adenocarcinoma of the prostate. J. Clin. Oncol. 12: 2005–2012.PubMedGoogle Scholar
  82. 82.
    Pisters, L., C. A. Pettaway, P. Troncoso, L. D. Finn, J. W. Slaton, and C. J. Logothetis. 1999. Preoperative chemotherapy and hormonal therapy followed by radical prostatectomy for locally advanced prostate cancer. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 18: Al212.Google Scholar
  83. 83.
    Presant, C.A., A. Van Amburg, C. Klahr, and G. E. Metter. 1980. Chemotherapy of advanced prostatic cancer with adriamycin, BCNU and cyclophosphamide. Cancer 46: 2389–2392.PubMedCrossRefGoogle Scholar
  84. 84.
    Qazi, R. and J. Khandekar. 1983. Phase II study of cisplatin for metastatic prostatic carcinoma. An Eastern Cooperative Oncology Group study. Am. J. Clin. Oncol. 6: 203–205.PubMedCrossRefGoogle Scholar
  85. 85.
    Rangel, C., H. Matzkin, and M. S. Soloway. 1992. Experience with weekly doxorubicin (adriamycin) in hormone refractory stage D2 prostate cancer. Urology 39: 577–582.PubMedCrossRefGoogle Scholar
  86. 86.
    Rossof, A. H., R. W. Talley, and R. Stephens. 1979. Phase II evaluation of cisdichlorodiammineplatinum(II) in advanced malignancies of the genitourinary and gynecologic organs: a Southwest Oncology Group study. Cancer Treat. Rep. 63: 1557–1564.PubMedGoogle Scholar
  87. 87.
    Roth, B. J., B. Y. Yeap, G. Wilding, B. Kasimis, D. McLeod, and P. J. Loehrer. 1993. Taxol in advanced, hormone refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group. Cancer 72: 2457–2460.PubMedCrossRefGoogle Scholar
  88. 88.
    Rowinsky, E. K. and R. C. Donehower. 1995. Paclitaxel (Taxol). New Engl. J. Med. 332: 1004–1014.PubMedCrossRefGoogle Scholar
  89. 89.
    Ryu, S., M. Gabel, M. S. Khil, Y. J. Lee, S. H. Kim, and J. H. Kim. 1994. Estramustine: a novel radiation enhancer in human carcinoma cells. Int. J. Radiat. Oncol. Biol. Phys. 30: 99–104.PubMedCrossRefGoogle Scholar
  90. 90.
    Savarese, D. M., M. Taplin, B. Marchesni, et al. 1999. A phase II study of docetaxel, estramustine and low dose hydrocortisone in hormone refractory prostate cancer: CALGB 9780. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 18: Al234.Google Scholar
  91. 91.
    Scher, H. I., C. Sternberg, W. D. Heston, et al. 1986. Etoposide in prostatic cancer: experimental studies and phase II trial in patients with bidimensionally measurable disease. Cancer Chemother. Pharmacol. 18: 24–26.PubMedCrossRefGoogle Scholar
  92. 92.
    Scher, H. I., A. Yagoda, T. Ahmed, and R. C. Watson. 1985. Methylglyoxal-bis (guanylhydrazone) in hormone-resistant adenocarcinoma of the prostate. J. Clin. Oncol. 3: 224–228.PubMedGoogle Scholar
  93. 93.
    Schmidt, J. D., W. W. Scott, R. P. Gibbons, et al. 1979. Comparison of procarbazine, imadzole-carboxamide and cyclophosphamide in relapsing patients with advanced carcinoma of the prostate. J. Urol. 121: 185–189.PubMedGoogle Scholar
  94. 94.
    Scott, W. W., R. P. Gibbons, D. E. Johnson, et al. 1976. The continued evaluation of the effects of chemotherapy in patients with advanced carcinoma of the prostate. J. Urol. 116: 211–213.PubMedGoogle Scholar
  95. 95.
    Seidman, A. D., H. I. Scher, D. Petrylak, D. D. Dershaw, and T. Curley. 1992. Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. J. Urol. 147: 931–934.PubMedGoogle Scholar
  96. 96.
    Seifter, E., P. Bunn, M. Cohen, et al. 1984. A trial of combination chemotherapy followed by hormonal therapy for previously untreated metastatic carcinoma of the prostate. J. Clin. Oncol. 4: 1365–1373.Google Scholar
  97. 97.
    Sella, A., R. Kilbourn, R. Amato, et al. 1994. Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer. J. Clin. Oncol. 12: 683–688.PubMedGoogle Scholar
  98. 98.
    Sinibaldi, V. J., M. A. Carducci, S. Moore-Cooper, et al. 1999. A phase II study evaluating a one day course of estramustine phosphate and docetaxel in patients with hormone refractory prostate cancer. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 18: Al239.Google Scholar
  99. 99.
    Slack, N.H. and G. P. Murphy. 1983. A decade of experience with chemotherapy for prostate cancer. Urology 22: 1–7.PubMedCrossRefGoogle Scholar
  100. 100.
    Smith, D. C., R. L. Dunn, M. S. Strawderman, and K. J. Pienta. 1998. Change in serum prostate specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J. Clin. Oncol. 16: 1835–1843.PubMedGoogle Scholar
  101. 101.
    Smith, D. C., P. Esper, M. Strawderman, B. Redman, and K. J. Pienta. 1999. Phase II trial of oral estramustine, oral etoposide and intravenous paclitaxel in hormone refractory prostate cancer. J. Clin. Oncol. 17: 1664–1671.PubMedGoogle Scholar
  102. 102.
    Soloway, M. S., S. Beckley, M. F. Brady, et al. 1983. A comparison of estramustine phosphate versus cis-platinum alone versus estramustine phosphate plus cis-platinum in patients with advanced hormone refractory prostate cancer who had extensive irradiation to the pelvis or lumbosacral area. J. Urol. 129: 56–61.PubMedGoogle Scholar
  103. 103.
    Soloway, M. S., J. B. deKernion, R. P. Gibbons, et al. 1981. Comparison of estramustine phosphate and vincristine alone or in combination for patients with advanced, hormone refractory, previously irradiated carcinoma of the prostate. J. Urol. 125: 664–667.PubMedGoogle Scholar
  104. 104.
    Soloway, M. S., R. M. Shippel, and M. Ikard. 1979. Cyclophosphamide, doxorubicin hydrochloride and 5-fluorouracil in advanced carcinoma of the prostate. J. Urol. 122: 637–639.PubMedGoogle Scholar
  105. 105.
    Speicher, L. A., L. Barone, and K. D. Tew. 1992. Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines. Cancer Res. 52: 4433–4440.PubMedGoogle Scholar
  106. 106.
    Stearns, M. E., and K. D. Tew. 1988. Estramustine binds MAP-2 to inhibit microtubule assembly in vitro. J. Cell Sci. 89: 331–341.PubMedGoogle Scholar
  107. 107.
    Stephens, R. L., C. Vaughn, M. Lane, et al. 1984. Adriamycin and cyclophosphamide versus hydroxyurea in advanced prostatic cancer. A randomized Southwest Oncology Group study. Cancer 53: 406–410.PubMedCrossRefGoogle Scholar
  108. 108.
    Tannock, I. F., D. Osoba, M. R. Stockier, et al. 1996. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol. 14: 1756–1764.PubMedGoogle Scholar
  109. 109.
    Torti, F., D. Aston, and B. L. Lum. 1983. Weekly doxorubicin in endocrine refractory carcinoma of the prostate. J. Clin. Oncol. 1: 477–482.PubMedGoogle Scholar
  110. 110.
    Trump, D. L., J. C. Marsh, L. K. Kvols, et al. 1990. A phase II trial of carboplatin (NSC 241240) in advanced prostate cancer, refractory to hormonal therapy. An Eastern Cooperative Oncology Group pilot study. Invest. New Drugs (8 Suppl. 1 ): S91 — S94.Google Scholar
  111. 111.
    Veronesi, A., V. Dal Bo, G. Lo Re, et al. 1989. Mitomycin C treatment of advanced, hormone-resistant prostatic carcinoma: a phase II study. Cancer Chemother. Pharmacol. 23: 115–116.PubMedCrossRefGoogle Scholar
  112. 112.
    Walther, P. J., S. D. Williams, M. Troner, F. A. Greco, R. Birch, and L. H. Einhorn. 1986. Phase II study of etoposide for carcinoma of the prostate. Cancer Treat. Rep. 70: 771–772.Google Scholar
  113. 113.
    Widmark, A., J. E. Damber, A. Bergh, and R. Henriksson. 1994. Estramustine potentiates the effects of irradiation on the Dunning (R3327) rat prostatic adenocarcinoma. Prostate 24: 79–83.PubMedCrossRefGoogle Scholar
  114. 114.
    Wieder, J. A. and M. S. Soloway. 1998. Incidene, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer. J. Urol. 160: 299–315.PubMedCrossRefGoogle Scholar
  115. 115.
    Yagoda, A. and D. Petrylak. 1993. Cytotoxic chemotherapy for advanced hormone-refractory prostate cancer. Cancer 71: 1098–1109.PubMedCrossRefGoogle Scholar
  116. 116.
    Yagoda, A. R., R. C. Watson, and R. B. Natalie. 1979. A critical analysis of response criteria in patients with prostatic cancer treated with cis-diamminechloride platinumll. Cancer 44: 1553–1562.PubMedCrossRefGoogle Scholar
  117. 117.
    Zagars, G. K. and A. C. Von Eschenbach. 1993. Prostate specific antigen. An important marker for prostate cancer treated by external beam radiation therapy. Cancer 72: 538–548.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Jeffrey M. Kamradt
  • Kenneth J. Pienta

There are no affiliations available

Personalised recommendations